UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
31 December
2024 - Completion of additional 33% stake in China JV
|
99.1
Haleon plc: Completion of additional 33% stake in China
JV
31 December 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
that it has completed the acquisition of an additional
33%1 equity
interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its joint
venture in China from its partners, Tianjin Pharmaceutical Group
("TPG") and Tianjin Pharmaceutical Da Ren Tang Group Corporation
Limited ("DRTG").
On 27 September 2024, Haleon announced that it had entered into an
agreement to acquire an additional 33%1 equity
interest in TSKF for a total consideration of RMB 4,465 million (c.
£0.5 billion). The transaction is expected to be accretive to
EPS.
This announcement follows the approval by DRTG's shareholders at
the DRTG Extraordinary General Meeting on 22 November 2024. All
other applicable necessary clearances have also been
obtained.
As noted in the initial announcement, Haleon and DRTG have agreed
that Haleon has an option to acquire and DRTG an option to sell the
remaining 12% shareholding in TSKF.
Notes
|
1.
|
This transaction consists of a simultaneous and inter-conditional
purchase of the entire 20% equity interest in TSKF held by TPG and
a 13% equity interest in TSKF held by DRTG.
|
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Rakesh
Patel
|
+44
7552 484646
|
Zoë Bird
|
+44
7736 746167
|
|
Emma
White
|
+44
7823 523562
|
Gemma
Thomas
|
+44 7985 175048
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
About TSKF
Founded in 1984, TSKF is a joint venture of Haleon, TPG and DRTG
in China. TSKF is a leading OTC company that manufactures and
distributes renowned products under Haleon's brands in China,
such as Fenbid, Contac, Bactroban, Voltaren and Flixonase in major
therapeutic areas such as Pain Relief, Respiratory Health and Skin
Health.
About TPG
TPG is a large-scale pharmaceutical group based in China. TPG
is engaged in the research and development, manufacturing and
commercialisation across four major business sectors including
traditional Chinese medicine, chemical and biological
pharmaceuticals, high-end medical devices, and modern commercial
logistics. The Company is ranked among China's top 500
enterprises.
About DRTG
DRTG (SHSE: 600329 / SGX: T14) is the core pharmaceutical
manufacturing arm of TPG. DRTG is engaged in the research,
development and manufacturing of Chinese herbal medicines,
proprietary Chinese medicines, western medicine, and other products
primarily in China. The company is also involved in the
wholesale and retail of medicines in China. DRTG was founded
in 1981 and listed on the Singapore Stock Exchange and the Shanghai
Stock Exchange.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
December 31, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|